IP Library Granted Patent US 7,785,618
Granted Patent B2
US 7,785,618 · App. 10/922,378 · Granted Aug 31, 2010

Conjugates comprising a biodegradable polymer and uses therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,785,618
App. No.
10/922,378
Granted
Aug 31, 2010
Kind
B2
Abstract

Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders.

Claims (10)

1. A conjugate comprising an enzyme, which is covalently linked to a biodegradable polymer via a succinyl tether between the enzyme and the biodegradable polymer, wherein the biodegradable polymer is a polyacetal, and wherein the polyacetal is poly(hydroxymethylethylene hydroxymethylacetal).

2. The conjugate of claim 1 , wherein the biodegradable polymer is negatively charged.

3. The conjugate of claim 1 , wherein the biodegradable polymer is positively charged.

4. The conjugate of claim 1 , wherein the biodegradable polymer has a molecular weight from about 2 kDa to about 250 kDa.

5. The conjugate of claim 3 , wherein the biodegradable polymer has a molecular weight from about 20 kDa to about 100 kDa.

6. The conjugate of claim 1 , further comprising a targeting agent.

7. The conjugate of claim 1 , wherein the enzyme is an apyrase; the polyacetal is poly(hydroxymethylethylene hydroxymethylacetal); and the apyrase is a soluble form of CD39.

8. The conjugate of claim 7 , wherein the apyrase comprises an amino acid sequence that is at least about 90% identical to SEQ ID NO: 2 and catalyzes hydrolysis of nucleoside diphosphates (NDPs).

9. The conjugate of claim 8 , wherein the apyrase comprises the catalytic domain set forth in SEQ ID NO: 2.

10. A pharmaceutical preparation comprising a conjugate of claim 1 and a pharmaceutically acceptable carrier.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2012
From: PAPISOV, MIKKHAIL L.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 028470/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2011
From: THE GENERAL HOSPITAL CORPORATION
To: ELMALEH, DAVID, DR.
Reel/Frame 027235/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2011
From: ELMALEH, DAVID, PH.D
To: MERSANA THERAPEUTICS, INC.
Reel/Frame 027235/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2011
From: ROBSON, SIMON C.
To: BETH ISRAEL DEACONESS MEDICAL CENTER
Reel/Frame 027061/0645 →
Continuity (3)
Continuation PCTUS030484500 · Feb 19, 2003
Provisional Application 6035830300 · Feb 20, 2002
Related Publication 20050169968A1 · Aug 4, 2005